ArticleKidney diseases (Basel, Switzerland)
Combined Effects of Pulmonary Hypertension and Heart Valve Calcification on Cardiovascular Outcomes in Maintenance Hemodialysis Patients: A Risk Stratification Study Using Echocardiography.
Article in Kidney diseases (Basel, Switzerland). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cardiovascular disease remains the leading cause of mortality in maintenance hemodialysis (MHD) patients. While both pulmonary hypertension (PH) and heart valve calcification (HVC) are established independent risk factors for adverse outcomes in this population, the synergistic effect of these two echocardiographic parameters on cardiovascular prognosis has not been well investigated. Methods: In this prospective study, we analyzed clinical and echocardiographic data from 302 MHD patients over a two-year follow-up period. Patients were stratified into three groups based on the presence of risk factors: group 1 (no risk factors), group 2 (either PH or HVC), and group 3 (both PH and HVC). Survival analysis was performed using Kaplan-Meier curves, and Cox regression models were employed to evaluate the impact on all-cause mortality, cardiovascular mortality, and new-onset cardiovascular events (CV events). Results: During follow-up, 63 patients (20.9%) died from all causes, with 36 deaths (57.1%) attributed to CV events. Cardiovascular mortality was significantly higher in groups 2 (13.2%) and 3 (30.2%) compared to group 1 (5.1%; Conclusion: The coexistence of PH and HVC significantly increases cardiovascular risk compared to either condition alone in MHD patients. Echocardiography is a valuable tool for screening and risk stratification in this high-risk population by identifying both PH and HVC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.